The agreement extends CNSide cerebrospinal fluid test coverage to 16 million additional patients nationwide.
CNSide Diagnostics has secured a national coverage agreement with Humana for its CNSide cerebrospinal fluid tumor cell enumeration laboratory developed test, expanding access to the assay for patients with metastatic central nervous system cancer.
The agreement, effective Oct 29, covers approximately 16 million people throughout the US and brings the CNSide CSF TCE LDT total policy coverage to 67 million people. CNSide Diagnostics is a wholly owned subsidiary of Plus Therapeutics Inc.
The CNSide CSF Assay Platform supports rapid diagnoses, treatment monitoring, and treatment guidance for patients with leptomeningeal metastases. The test demonstrates 92% sensitivity and 95% specificity while influencing treatment decisions in 90% of cases, according to the company.
Since 2020, more than 11,000 CNSide tests have been performed at over 120 US cancer institutions. The superior clinical utility of CNSide over standard of care has been demonstrated in nine peer-reviewed publications and the FORESEE clinical trial, Plus Therapeutics reports.
The laboratory developed test is designed to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The platform enables quantitative analysis of cerebrospinal fluid to inform management of patients with leptomeningeal metastases.
The test is available exclusively through CNSide Diagnostics as a testing service provided to healthcare professionals in the US.
Plus Therapeutics, headquartered in Houston, is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system. The company is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases and recurrent glioblastoma.
ID 72034026 © Thomaskelley | Dreamstime.com
